Solutions

Online Inquiry

Global Services. (Creative Biolabs Authorized)

Humoral & Cellular Anti-CAR Immunogenicity Evaluation Services

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides Humoral & Cellular Anti-CAR Immunogenicity Evaluation Services to support comprehensive immune monitoring during CAR therapeutic development. This service addresses challenges in evaluating CAR immunogenicity, predicting immune-mediated CAR-T cell clearance, and understanding patient immune responses against engineered receptors. Through integrated immunoassays, cellular immune monitoring platforms, and functional evaluation strategies, Creative Biolabs enables characterization of antibody- and T cell-mediated anti-CAR responses, supporting safety assessment, persistence analysis, and translational advancement of next-generation CAR therapies.

Introduction

CAR-based therapies have demonstrated remarkable clinical potential; however, immune recognition of engineered receptors may influence CAR cell persistence, expansion, and therapeutic performance. Published studies have reported that non-human-derived CAR components, especially antigen-binding regions, can contribute to humoral and cellular immune responses. Comprehensive evaluation combining antibody detection, T cell activation analysis, and functional immune assays provides valuable insights for CAR development and optimization.

Fig.1 Immune responses triggered by murine scFv cause premature clearance of CAR-T cells and hinder repeated dosing. (OA Literature) Fig.1 Murine scfv-induced immune activation leads to early elimination of CAR-T cells and limits re-dosing feasibility.¹

Service

Our services streamline preclinical development by comprehensively evaluating both humoral and cellular immune responses against CAR molecules. We specialize in detecting and characterizing anti-CAR antibodies, assessing their binding profiles, and analyzing immune recognition. On the cellular side, we identify CAR-specific T cell activation and evaluate cytokine secretion alongside overall immune cell functionality.

This deep immunological insight directly supports CAR design optimization and safety profiling. We help teams compare the immune recognition potential of different constructs, providing the precise data needed for sequence optimization, humanization strategies, and de-immunization studies. Ultimately, our targeted assessments mitigate immunogenicity risks early on, ensuring a smoother transition from design to successful preclinical evaluation.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Evaluation of Humoral & Cellular Anti-CAR Immunogenicity Evaluation Services. (Creative Biolabs Original)

We provide anti-CAR immunogenicity profiling by integrating humoral and cellular analyses to mitigate immune risks. Our platforms detect and characterize anti-CAR antibodies, evaluating their binding traits and functional impact on CAR signaling, cytokine release, and target-cell killing. Concurrently, we track cellular immunity via peptide stimulation and multiparameter flow cytometry, measuring T cell activation markers.

Our Workflow

Required Starting Materials:

CAR construct information, including CAR sequence, antigen-binding domain information, extracellular/intracellular components, and design background.
Biological samples or experimental materials, such as engineered CAR cells, donor-derived immune cells, or serum/plasma samples.
Project objectives and evaluation requirements, including desired immune response endpoints, study model, and comparison groups.

Workflow of Humoral & Cellular Anti-CAR Immunogenicity Evaluation Services. (Creative Biolabs Original)

You will receive an anti-CAR immunogenicity evaluation report, an immune response summary, a raw data package, and an integrated risk analysis with CAR development optimization recommendations.

Specialty Services

Anti-CAR ADA (Anti-Drug Antibody) Assay

This highly sensitive assay detects and quantifies pre-existing or treatment-induced antibodies against the CAR construct. It delivers critical immunogenicity data necessary to predict therapeutic persistence and ensure patient safety throughout clinical development.

Learn More →

Anti-Vector ADA Assay: Capsid & Envelope Glycoprotein Antibody Detection

Designed to screen for neutralizing antibodies against vector capsids and envelope proteins, this service evaluates pre-existing immunity that could block vector delivery. It ensures optimal patient stratification and vector efficacy during in vivo gene therapy trials.

Learn More →

CAR-Specific Cellular Immune Response Assay (T-Cell Response)

Tracking cell-mediated immunity, this assay evaluates host T-cell responses directed against CAR-expressing cells. By detecting potential cellular rejection, it provides deep immunological insights to safeguard the in vivo persistence and long-term efficacy of your therapies.

Learn More →

Core Benefits

Advanced assay development capabilities to support CAR immunogenicity risk assessment, including assay optimization, validation, and application-specific workflow establishment.
Functional immune response evaluation to investigate whether Anti-CAR immune responses affect CAR recognition, activation, persistence, or therapeutic activity.
Multi-parameter immune monitoring solutions combining immunoassays, flow cytometry-based analysis, cellular activation assays, and immune profiling approaches.

FAQs

Q: Why is Anti-CAR immunogenicity evaluation important for CAR therapy development?

A: Anti-CAR immune responses may influence CAR cell persistence, expansion, and therapeutic activity. Early evaluation helps identify potential immune recognition risks and supports improved CAR design strategies.

Q: Can the service evaluate both antibody and T cell immune responses?

A: Yes. The service integrates humoral immune response analysis with cellular immune monitoring to provide a broader understanding of CAR immunogenicity.

Q: Can Anti-CAR immunogenicity testing support CAR humanization or optimization projects?

A: Yes. Immunogenicity evaluation data can help compare CAR designs, identify immune recognition concerns, and support optimization strategies.

Partner with Us

We deliver a comprehensive, customizable Humoral & Cellular Anti-CAR Immunogenicity Evaluation platform to support cell therapy developers. By combining robust antibody detection with highly sensitive T-cell activation profiling, we provide the definitive data packages necessary to support confident IND applications and clinical trial progression. Our dedicated team of project managers and immunologists is ready to collaborate with you to design a tailored bioanalytical study optimized for your specific therapeutic target. Contact us today to discuss your project requirements.

Reference

Khan, Aalia N et al. "Immunogenicity of CAR-T Cell Therapeutics: Evidence, Mechanism and Mitigation." Frontiers in Immunology vol. 13 886546. 23 May. 2022. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3389/fimmu.2022.886546

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.